The global sepsis diagnostics market is experiencing robust growth driven by the rising incidence of sepsis cases worldwide, increasing awareness about early detection, and advancements in diagnostic technologies. Sepsis, a life-threatening condition triggered by the body’s response to infection, demands rapid and accurate diagnostic solutions to improve patient survival rates. The development of innovative biomarkers, molecular diagnostics, and point-of-care testing has significantly enhanced early detection and treatment efficacy. In addition, the growing healthcare expenditure, coupled with the increasing adoption of automated diagnostic tools in hospitals and clinics, is propelling market expansion. However, challenges such as the high cost of advanced diagnostic tools and limited accessibility in low-income regions may hinder growth. Nevertheless, ongoing research and development efforts and the integration of AI and machine learning in diagnostics are expected to create new opportunities, driving the market forward in the coming years.
Global Sepsis Diagnostics Market is valued at 891.88 million in 2022 and is expected to reach USD 1,526.76 million by 2030, with a growing CAGR of 8.0% during the forecast period 2023 to 2030.
To know more, visit https://www.databridgemarketresearch.com/reports/global-sepsis-diagnostics-market
Below are the Top Sepsis Diagnostics Market Companies with a Significant Market Share:
|
Rank
|
Company
|
Overview
|
Product Portfolio
|
Sales Geographical Coverage
|
Developments
|
|
1.
|
F. Hoffmann-La Roche Ltd.
|
F. Hoffmann-La Roche Ltd., a global healthcare leader headquartered in Basel, Switzerland, plays a significant role in the sepsis diagnostics market through its advanced diagnostic solutions. The company offers innovative molecular and immunoassay technologies, including biomarkers like procalcitonin (PCT) for early and accurate sepsis detection. Roche's focus on precision diagnostics and continuous research strengthens its position as a key player in combating sepsis globally.
|
|
Americas, Middle East and Africa, Asia-Pacific, and Europe
|
In June 2016, Roche diagnostics has received FDA 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay, which is a dedicated solution for people with severe sepsis or septic shock. This product made Roche the first IVD company in U.S. to provide an integrated solution for sepsis management. Thereby, this approval enhanced its foothold in the market.
|
|
2.
|
Abbott
|
Abbott is a prominent player in the sepsis diagnostics market with its comprehensive range of diagnostic tools and platforms. The company’s point-of-care testing and laboratory diagnostics, such as rapid molecular assays, aid in the swift identification of sepsis pathogens and biomarkers. Abbott’s commitment to technological innovation and accessibility ensures timely and accurate diagnostics, enhancing patient outcomes.
|
|
Asia, Greater China, Europe, Middle East and South Africa, The Americas
|
In 2017, Abbott launches Point-of-care sensors that provided diagnosis of sepsis as it is a life-threatening organ dysfunction caused by a dysregulated host response to infection. This launch was a great help to the patients as well as earned a good revenue to the company.
|
|
3.
|
BIOMÉRIEUX
|
BIOMÉRIEUX specializes in in vitro diagnostics and is a major contributor to sepsis detection technologies. The company offers a range of diagnostic solutions, including automated blood culture systems and molecular biology assays that enable rapid identification of sepsis-causing pathogens. BIOMÉRIEUX's continuous innovation and global reach make it a crucial player in the sepsis diagnostics landscape.
|
|
|
In November 2016, bioMérieux announced that it has received market clearance from the U.S. Food and Drug Administration (FDA) for the VIDAS B•R•A•H•M•S PCT for the direct detection of bacterial species in human whole blood. This launch helped the company to increase its revenue.
|
|
4.
|
Thermo Fisher Scientific Inc.
|
Thermo Fisher Scientific Inc., provides a diverse portfolio of diagnostic tools that address the critical need for fast and accurate sepsis detection. The company's advanced molecular diagnostics, immunoassays, and laboratory equipment facilitate early diagnosis and effective management of sepsis. Thermo Fisher’s commitment to research and technological advancement solidifies its role in the global sepsis diagnostics market.
|
|
North America, South America, Middle East and Africa, Asia-Pacific, and Europe
|
In January 2021, Thermo Fisher Scientific Inc. announced its definitive agreement to acquire Mesa Biotech, Inc., for the enhancement of Sepsis Diagnostics services.
The acquisition helped the company to grow its product portfolio.
|
|
5.
|
BD
|
BD is a global leader in medical technology and diagnostics, offering robust solutions for sepsis detection. The company’s products include blood culture systems, rapid diagnostic assays, and biomarker detection tools that help in the timely identification of sepsis. BD’s focus on innovation and improving diagnostic accuracy enhances its influence in the global sepsis diagnostics market.
|
|
North America, South America, Middle East and Africa, Asia-Pacific, and Europe
|
In March 2019, BD launched a new automated flow cytometry sample preparation instrument called BD FACSDuet with CE-IVD Certification. This instrument used in the laboratory for diagnosis purposes with less errors. This launch has helped company to increase its revenue and grow the global presence.
|
Conclusion
The global sepsis diagnostics market is experiencing robust growth, driven by advancements in rapid diagnostic technologies and a heightened focus on early detection to improve patient outcomes. The rising prevalence of sepsis, particularly in aging populations and immunocompromised individuals, has intensified the demand for accurate and efficient diagnostic tools. Additionally, increasing healthcare awareness, supportive government initiatives, and significant investments in research and development are fueling market expansion.
